"Our team brings extensive expertise and diverse experience to every aspect of our work."
Board and Executive Management
BioNxt’s board and executive management bring significant expertise in science, therapeutics, business development and growth. Combine the collective skills of the team with an entrepreneurial eye for opportunity and you can see why BioNxt is poised to be a disrupter in the pharmaceutical industry.
Hugh Rogers
Mr. Rogers is an entrepreneur and lawyer with private and public start-up experience in a range of industries and operational roles.
Recent advisory work has focused on public listings and corporate restructuring in the life science (cell therapy and medical device) and natural resource (natural gas co-gen and conventional oil) industries. Mr. Rogers has held several board and executive management positions with junior exchange listed issuers. He holds a bachelor’s degree in Cell Biology and Genetics and a Law degree. He is a member in good standing of the Law Society of British Columbia.
Dr. Florian A. Sahr
Dr. Florian A. Sahr is a German-born expert in drug formulation, technology transfer, and new-product manufacturing. With extensive experience in transdermal (TDS) and oral dissolvable (ODF) drug delivery systems, he has established GMP and FDA-compliant pharmaceutical manufacturing facilities.
Notable roles include Senior Scientist and Head of Manufacturing at Gen-Plus GmbH, where he developed and transferred TDS and ODF formulations, and Project Manager at tesa Labtec GmbH, managing technology transfer of generic TDS formulations. Dr. Sahr has also served as Head of Manufacturing under the German Medicines Act for clinical trial materials.
Dr. Oleksandr Zabutkin
Dr. Oleksandr Zabudkin is a pharmaceutical expert with over 25 years of experience, specializing in oncology APIs and advanced manufacturing processes. Initially a medical oncologist, he transitioned to pharmaceutical development, founding Synbias Pharma Ltd., where he implemented GMP standards and oversaw the synthesis of complex compounds.
In 2020, he established Entomus s.r.o. in the Czech Republic, focusing on the development of highly potent APIs and advanced pharmaceutical formulations. He also leads OncoGenerix, setting new benchmarks in injectable manufacturing and regulatory compliance.
Dr. Wolfgang Wagner
Dr. Wolfgang Wagner is an accomplished chemist and pharmaceutical professional, currently serving as Head of Development and Manufacturing at Vektor Pharma TF GmbH. With a PhD in Chemistry from Julius-Maximilians-Universität Würzburg (magna cum laude), he specializes in the development of orally disintegrating films (ODF) and transdermal systems (TDS), along with expertise in GMP-compliant manufacturing and intellectual property protection.
Previously, Dr. Wagner held roles such as Project Manager and Deputy Head of Quality Control at Vektor Pharma, focusing on pharmaceutical development and analytical method implementation. His technical expertise spans organic synthesis, analytical methods, and advanced project management in pharmaceutical R&D. Fluent in German and English, he brings interdisciplinary leadership to cutting-edge drug delivery solutions.
Prof. Dr. Raimar Löbenberg
Dr. Löbenberg, a PhD in Pharmaceutics from Goethe-University Frankfurt, is a professor at the University of Alberta and founder of the Drug Development and Innovation Centre. His research focuses on biopharmaceutics, oral drug performance, and inhalable nanoparticles for lung diseases. He co-founded RS Therapeutics Inc., specializing in foam-based topical drug delivery.
Dr. Löbenberg has held roles such as president of the Canadian Society for Pharmaceutical Sciences, vice chair of the USP Dietary Supplement Expert Committee, and member of Health Canada advisory committees on pharmaceutical sciences and opioid abuse.
Wolfgang Probst
Mr. Probst is an experienced management consultant specialized in investment consulting and capitalization.
He’s an expert in mergers and acquisitions, corporate re-organizations, and divestitures and has adroitly brought multiple startups to success. Owing to his superior negotiating skills, he has a proven track record in strategic analysis, which resulted in highly targeted organizational restructuring.
“We’re reshaping drug delivery to bring better outcomes and brighter futures to patients worldwide. We are building a leading bioscience company that combines transformative science with the commitment and passion of our experienced team, partners, and investors.”
– Hugh Rogers, CEO
Invest in Bionxt, invest in innovation
Learn more about Bionxt’s innovation to impact strategy and get access to Bionxt investor information.
CSE:BNXT FSE:BXT OTCQB:BNXTF